Clinical Trial Update: Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) [NA]

View source ↗

Summary

This completed clinical trial investigates using plasmatic cell-free BRAF and NRAS mutations as a blood-based biomarker to monitor patients with metastatic mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Malignant Melanoma Stage IV, Malignant Melanoma Stage III | NA | Status: COMPLETED